Role of vitamins in cardiovascular health and disease

References

• Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35(15):960–968.
   PubMed Web of Science ®Google Scholar
• Sies H, Jones D. . Oxidative stress. In: Fink G, editor. Encyclopedia of Stress. San Diego: Elsevier; 2007:45–48.
   Google Scholar
• Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. 2014;395(2):203–230.
   PubMed Web of Science ®Google Scholar
• Welch GN, Upchurch GR Jr, Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract (1995). 1997;32(6):81–2, 85, 88–92.
   Web of Science ®Google Scholar
• Outinen PA, Sood SK, Liaw PC, et al. Characterization of the stress-inducing effects of homocysteine. Biochem J. 1998;332(Pt 1):213–221.
   PubMed Web of Science ®Google Scholar
• Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol. 2005;289(6):H2649–H2656.
   PubMed Web of Science ®Google Scholar
• Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL, O K. Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res. 2004;94(1):28–36.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328(20):1444–1449.
   PubMed Web of Science ®Google Scholar
• Osganian SK, Stampfer MJ, Rimm E, et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol. 2003;42(2):246–252.
   Web of Science ®Google Scholar
• Pfister R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Plasma vitamin C predicts incident heart failure in men and women in European Prospective Investigation into Cancer and Nutrition-Norfolk prospective study. Am Heart J. 2011;162(2):246–253.
   Web of Science ®Google Scholar
• Myint PK, Luben RN, Wareham NJ, Khaw KT. Association between plasma vitamin C concentrations and blood pressure in the European prospective investigation into cancer-Norfolk population-based study. Hypertension. 2011;58(3):372–379.
   Web of Science ®Google Scholar
• Juraschek SP, Guallar E, Appel LJ, Miller ER 3rd. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;95(5):1079–1088.
   PubMed Web of Science ®Google Scholar
• Hercberg S, Kesse-Guyot E, Druesne-Pecollo N, et al. Incidence of cancers, ischemic cardiovascular diseases and mortality during 5-year follow-up after stopping antioxidant vitamins and minerals supplements: a postintervention follow-up in the SU.VI.MAX Study. Int J Cancer. 2010;127(8):1875–1881.
   PubMed Web of Science ®Google Scholar
• Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328(20):1450–1456.
   PubMed Web of Science ®Google Scholar
• Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347(9004):781–786.
   PubMed Web of Science ®Google Scholar
• Salonen JT, Nyyssönen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med. 2000;248(5):377–386.
   Web of Science ®Google Scholar
• Salonen RM, Nyyssönen K, Kaikkonen J, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation. 2003;107(7):947–953.
   PubMed Web of Science ®Google Scholar
• Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356(9237):1213–1218.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Iso H, Date C, et al. Dietary intakes of antioxidant vitamins and mortality from cardiovascular disease: the Japan Collaborative Cohort Study (JACC) study. Stroke. 2011;42(6):1665–1672.
   PubMed Web of Science ®Google Scholar
• Knekt P, Ritz J, Pereira MA, et al. Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am J Clin Nutr. 2004;80(6):1508–1520.
   PubMed Web of Science ®Google Scholar
• Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women’s Antioxidant Cardiovascular Study. Arch Intern Med. 2007;167(15):1610–1618.
   PubMedGoogle Scholar
• Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA. 1995;273(23):1849–1854.
   PubMed Web of Science ®Google Scholar
• Ellingsen I, Seljeflot I, Arnesen H, Tonstad S. Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study. Nutr Metab Cardiovasc Dis. 2009;19(1):8–14.
   Web of Science ®Google Scholar
• Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121–1135.
   PubMed Web of Science ®Google Scholar
• Rodrigo R, Cereceda M, Castillo R, et al. Prevention of atrial fibrillation following cardiac surgery: basis for a novel therapeutic strategy based on non-hypoxic myocardial preconditioning. Pharmacol Ther. 2008;118(1):104–127.
   Web of Science ®Google Scholar
• Rodrigo R, Vinay J, Castillo R, et al. Use of vitamins C and E as a prophylactic therapy to prevent postoperative atrial fibrillation. Int J Cardiol. 2010;138(3):221–228.
   Web of Science ®Google Scholar
• Rodrigo R. Prevention of postoperative atrial fibrillation: novel and safe strategy based on the modulation of the antioxidant system. Front Physiol. 2012;3:93.
   PubMed Web of Science ®Google Scholar
• Rodrigo R, Prieto JC, Castillo R. Cardioprotection against ischaemia/reperfusion by vitamins C and E plus n-3 fatty acids: molecular mechanisms and potential clinical applications. Clin Sci (Lond). 2013;124(1):1–15.
   PubMed Web of Science ®Google Scholar
• Rebrova T, Shipulin VM, Afanasiev SA, Vorobieva EV, Kiiko OG. Opyt primeneniia askorbinovoi kisloty kak antioksidanta u patsientov posle operatsii koronarnogo shuntirovaniia s ispol’zovaniem iskusstvennogo krovoobrashcheniia. [The experience of the application of ascorbinic acid as antioxidant after coronary artery surgery with use of cardiopulmonary bypass]. Kardiologiia. 2012;52(7):73–76. Russian.
   Google Scholar
• Eslami M, Badkoubeh RS, Mousavi M, et al. Oral ascorbic acid in combination with beta-blockers is more effective than beta-blockers alone in the prevention of atrial fibrillation after coronary artery bypass grafting. Tex Heart Inst J. 2007;34(3):268–274.
   Web of Science ®Google Scholar
• Papoulidis P, Ananiadou O, Chalvatzoulis E, et al. The role of ascorbic acid in the prevention of atrial fibrillation after elective on-pump myocardial revascularization surgery: a single-center experience – a pilot study. Interact Cardiovasc Thorac Surg. 2011;12(2):121–124.
   Web of Science ®Google Scholar
• Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300(18):2123–2133.
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447–455.
   Web of Science ®Google Scholar
• Lonn E, Bosch J, Yusuf S, et al; HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293(11):1338–1347.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):23–33.
   PubMed Web of Science ®Google Scholar
• Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):56–65.
   PubMed Web of Science ®Google Scholar
• Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158(6):668–675.
   PubMed Web of Science ®Google Scholar
• Törnwall ME, Virtamo J, Korhonen PA, et al. Effect of alpha-tocopherol and beta-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study. Eur Heart J. 2004;25(13):1171–1178.
   Web of Science ®Google Scholar
• Leppälä JM, Virtamo J, Fogelholm R, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000;20(1):230–235.
   PubMed Web of Science ®Google Scholar
• Leppälä JM, Virtamo J, Fogelholm R, Albanes D, Taylor PR, Heinonen OP. Vitamin E and beta carotene supplementation in high risk for stroke: a subgroup analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Arch Neurol. 2000;57(10):1503–1509.
   Google Scholar
• Au-Yeung KK, Yip JC, Siow YL, O K. Folic acid inhibits homocysteine-induced superoxide anion production and nuclear factor kappa B activation in macrophages. Can J Physiol Pharmacol. 2006;84(1):141–147.
   Web of Science ®Google Scholar
• Shirodaria C, Antoniades C, Lee J, et al. Global improvement of vascular function and redox state with low-dose folic acid: implications for folate therapy in patients with coronary artery disease. Circulation. 2007;115(17):2262–2270.
   Web of Science ®Google Scholar
• Yilmaz H, Sahin S, Sayar N, et al. Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease. Acta Cardiol. 2007;62(6):579–585.
   Web of Science ®Google Scholar
• Title LM, Ur E, Giddens K, McQueen MJ, Nassar BA. Folic acid improves endothelial dysfunction in type 2 diabetes – an effect independent of homocysteine-lowering. Vasc Med. 2006;11(2):101–109.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Sherwood RA, Asonganyi B, Ouldred EL, Thomas S, Jackson SH. Folic acid: a marker of endothelial function in type 2 diabetes? Vasc Health Risk Manag. 2005;1(1):79–83.
   PubMedGoogle Scholar
• Das UN. Folic acid says NO to vascular diseases. Nutrition. 2003; 19(7–8):686–692.
   Web of Science ®Google Scholar
• Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Newcombe RG, Lewis MJ. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest. 1999;29(8):659–662.
   Web of Science ®Google Scholar
• Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 micromol/liter). The Hordaland Homocysteine Study. J Clin Invest. 1996;98(9):2174–2183.
   PubMed Web of Science ®Google Scholar
• Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol. 2000;36(3):758–765.
   Web of Science ®Google Scholar
• Moens AL, Vrints CJ, Claeys MJ, Timmermans JP, Champion HC, Kass DA. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am J Physiol Heart Circ Physiol. 2008;294(5):H1971–H1977.
   Web of Science ®Google Scholar
• Ji Y, Diao J, Han Y, et al. Pyridoxine prevents dysfunction of endothelial cell nitric oxide production in response to low-density lipoprotein. Atherosclerosis. 2006;188(1):84–94.
   Web of Science ®Google Scholar
• Qipshidze N, Tyagi N, Sen U, et al. Folic acid mitigated cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine-metabolizing enzymes postmyocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2010;299(5):H1484–H1493.
   Web of Science ®Google Scholar
• Moens AL, Champion HC, Claeys MJ, et al. High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation. 2008;117(14):1810–1819.
   Web of Science ®Google Scholar
• Gielis JF, Lin JY, Wingler K, Van Schil PE, Schmidt HH, Moens AL. Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic Biol Med. 2011;50(7):765–776.
   PubMed Web of Science ®Google Scholar
• Stroes ES, van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res. 2000;86(11):1129–1134.
   PubMed Web of Science ®Google Scholar
• Till U, Röhl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12. Atherosclerosis. 2005;181(1):131–135.
   Web of Science ®Google Scholar
• Ntaios G, Savopoulos C, Karamitsos D, et al. The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial. Int J Cardiol. 2010;143(1):16–19.
   Web of Science ®Google Scholar
• Qin X, Xu M, Zhang Y, et al. Effect of folic acid supplementation on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;222(2):307–313.
   Web of Science ®Google Scholar
• Marcucci R, Zanazzi M, Bertoni E, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation. 2003;75(9):1551–1555.
   PubMed Web of Science ®Google Scholar
• Tungkasereerak P, Ong-ajyooth L, Chaiyasoot W, et al. Effect of short-term folate and vitamin B supplementation on blood homocysteine level and carotid artery wall thickness in chronic hemodialysis patients. J Med Assoc Thai. 2006;89(8):1187–1193.
   Google Scholar
• Hodis HN, Mack WJ, Dustin L, et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke. 2009;40(3):730–736.
   PubMed Web of Science ®Google Scholar
• Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, Salonen JT; Kuopio Ischemic Heart Disease Risk Factor Study Group. Low dietary folate intake is associated with an excess incidence of acute coronary events: the Kuopio Ischemic Heart Disease Risk Factor Study. Circulation. 2001;103(22):2674–2680.
   PubMed Web of Science ®Google Scholar
• Bazzano LA, He J, Ogden LG, et al. Dietary intake of folate and risk of stroke in US men and women: NHANES I Epidemiologic Follow-up Study. National Health and Nutrition Examination Survey. Stroke. 2002;33(5):1183–1188.
   Google Scholar
• Voutilainen S, Virtanen JK, Rissanen TH, et al. Serum folate and homocysteine and the incidence of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr. 2004;80(2):317–323.
   Web of Science ®Google Scholar
• Imamura A, Murakami R, Takahashi R, et al. Low folate levels may be an atherogenic factor regardless of homocysteine levels in young healthy nonsmokers. Metabolism. 2010;59(5):728–733.
   Web of Science ®Google Scholar
• Giles WH, Kittner SJ, Anda RF, Croft JB, Casper ML. Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke. 1995;26(7):1166–1170.
   Web of Science ®Google Scholar
• Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299(17):2027–2036.
   PubMed Web of Science ®Google Scholar
• Bentley TG, Weinstein MC, Willett WC, Kuntz KM. A cost-effectiveness analysis of folic acid fortification policy in the United States. Public Health Nutr. 2009;12(4):455–467.
   PubMed Web of Science ®Google Scholar
• Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009;30(1):6–15.
   PubMed Web of Science ®Google Scholar
• Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279(5):359–364.
   PubMed Web of Science ®Google Scholar
• Holmquist C, Larsson S, Wolk A, de Faire U. Multivitamin supplements are inversely associated with risk of myocardial infarction in men and women – Stockholm Heart Epidemiology Program (SHEEP). J Nutr. 2003;133(8):2650–2654.
   Web of Science ®Google Scholar
• Rautiainen S, Akesson A, Levitan EB, Morgenstern R, Mittleman MA, Wolk A. Multivitamin use and the risk of myocardial infarction: a population-based cohort of Swedish women. Am J Clin Nutr. 2010;92(5):1251–1256.
   PubMed Web of Science ®Google Scholar
• He K, Merchant A, Rimm EB, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke. 2004;35(1):169–174.
   Web of Science ®Google Scholar
• Larsson SC, Männistö S, Virtanen MJ, Kontto J, Albanes D, Virtamo J. Folate, vitamin B6, vitamin B12, and methionine intakes and risk of stroke subtypes in male smokers. Am J Epidemiol. 2008;167(8):954–961.
   Web of Science ®Google Scholar
• Bønaa KH, Njølstad I, Ueland PM, et al; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578–1588.
   PubMed Web of Science ®Google Scholar
• Armitage JM, Bowman L, Clarke RJ, et al; Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010;303(24):2486–2494.
   PubMed Web of Science ®Google Scholar
• Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300(7):795–804.
   PubMed Web of Science ®Google Scholar
• Lonn E, Yusuf S, Arnold MJ, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–1577.
   PubMed Web of Science ®Google Scholar
• Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298(10):1163–1170.
   PubMed Web of Science ®Google Scholar
• Saposnik G, Ray JG, Sheridan P, et al; Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40(4):1365–1372.
   PubMedGoogle Scholar
• Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876–1882.
   PubMed Web of Science ®Google Scholar
• Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA. 2006;296(22):2720–2726.
   PubMed Web of Science ®Google Scholar
• Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565–575.
   PubMed Web of Science ®Google Scholar
• Spence JD, Stampfer MJ. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. JAMA. 2011;306(23):2610–2611.
   PubMed Web of Science ®Google Scholar
• Mark SD, Wang W, Fraumeni JF Jr, et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol. 1996;143(7):658–664.
   Web of Science ®Google Scholar
• Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke. 2010;41(6):1205–1212.
   PubMed Web of Science ®Google Scholar
• Qin X, Huo Y, Langman CB, et al. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2011;6(3):482–488.
   PubMed Web of Science ®Google Scholar
• Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006;24(4):379–386.
   Web of Science ®Google Scholar
• Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A. The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. J Nutr. 2003;133(9):2863–2867.
   PubMed Web of Science ®Google Scholar
• Debreceni B, Debreceni L. Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases? Cardiovasc Ther. 2012;30(4):227–233.
   Web of Science ®Google Scholar
• Helfand M, Buckley D, Fleming C, et al. Screening for Intermediate Risk Factors for Coronary Heart Disease: Systematic Evidence Synthesis. Evidence Synthesis No. 73. AHRQ Publication No. 10-05141-EF-1. Rockville, Maryland: Agency for Healthcare Research and Quality; 2009. Available from: http://www.ncbi.nlm.nih.gov/books/NBK35208. Accessed August 26, 2014.
   Google Scholar
• Fraga C, Blanco M, Vigo E, Segura C, García-Caballero T, Pérez-Fernández R. Ontogenesis of the vitamin D receptor in rat heart. Histochem Cell Biol. 2002;117(6):547–550.
   Web of Science ®Google Scholar
• Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology. 2008;149(2):558–564.
   PubMed Web of Science ®Google Scholar
• Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74(2):170–179.
   PubMed Web of Science ®Google Scholar
• de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011;22(9):1603–1609.
   PubMed Web of Science ®Google Scholar
• Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754–759.
   PubMed Web of Science ®Google Scholar
• Krause R, Bühring M, Hopfenmüller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet. 1998;352(9129):709–710.
   PubMed Web of Science ®Google Scholar
• Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006;29(3):650–656.
   PubMed Web of Science ®Google Scholar
• Liu L, Chen M, Hankins SR, et al; Drexel Cardiovascular Health Collaborative Education, Research, and Evaluation Group. Serum 25-hydroxyvitamin D concentration and mortality from heart failure and cardiovascular disease, and premature mortality from all-cause in United States adults. Am J Cardiol. 2012;110(6):834–839.
   PubMed Web of Science ®Google Scholar
• Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care. 2008;11(1):7–12.
   PubMed Web of Science ®Google Scholar
• Lee JH, O’Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52(24):1949–1956.
   PubMed Web of Science ®Google Scholar
• Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am J Med. 2002;112(8):659–662.
   PubMed Web of Science ®Google Scholar
• Kienreich K, Tomaschitz A, Verheyen N, et al. Vitamin D and cardiovascular disease. Nutrients. 2013;5(8):3005–3021.
   PubMed Web of Science ®Google Scholar
• Chua GT, Chan YC, Cheng SW. Vitamin D status and peripheral arterial disease: evidence so far. Vasc Health Risk Manag. 2011;7:671–675.
   Google Scholar
• van de Luijtgaarden KM, Voûte MT, Hoeks SE, et al. Vitamin D deficiency may be an independent risk factor for arterial disease. Eur J Vasc Endovasc Surg. 2012;44(3):301–306.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–511.
   PubMed Web of Science ®Google Scholar
• Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629–1637.
   PubMed Web of Science ®Google Scholar
• Amer M, Qayyum R. Relationship between 25-hydroxyvitamin D and all-cause and cardiovascular disease mortality. Am J Med. 2013;126(6):509–514.
   Web of Science ®Google Scholar
• Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 2014;348g1903.
   Google Scholar
• Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol. 2012;109(3):359–363.
   PubMed Web of Science ®Google Scholar
• Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010;152(5):315–323.
   PubMed Web of Science ®Google Scholar
• Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(7):1931–1942.
   Web of Science ®Google Scholar
• Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.
   PubMed Web of Science ®Google Scholar
• Pilz S, Tomaschitz A, Drechsler C, Dekker JM, März W. Vitamin D deficiency and myocardial diseases. Mol Nutr Food Res. 2010;54(8):1103–1113.
   Web of Science ®Google Scholar
• Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2011;7:CD007470.
   Google Scholar
• Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2014;1:CD007470.
   Google Scholar
• Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. 2014;348:g2035.
   PubMed Web of Science ®Google Scholar
• Cashman KD. A review of vitamin D status and CVD. Proc Nutr Soc. 2014;73(1):65–72.
   Web of Science ®Google Scholar
• Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1):159–171.
   PubMed Web of Science ®Google Scholar
• Freedman JE, Farhat JH, Loscalzo J, Keaney JF Jr. Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation. 1996;94(10):2434–2440.
   PubMed Web of Science ®Google Scholar
• Traber MG. Vitamin E and K interactions – a 50-year-old problem. Nutr Rev. 2008;66(11):624–629.
   Web of Science ®Google Scholar
• Booth SL, Golly I, Sacheck JM, et al. Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. Am J Clin Nutr. 2004;80(1):143–148.
   PubMed Web of Science ®Google Scholar
• Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. Am J Manag Care. 2002;8(Suppl 22):S691–S700.
   Web of Science ®Google Scholar
• Ogawa M, Abe S, Saigo M, et al. Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age. Thromb Res. 2003;109(5–6):253–258.
   Web of Science ®Google Scholar
• Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77(6):1909–1916.
   Web of Science ®Google Scholar
• Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75(4):895–901.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997;95(7):1777–1782.
   Web of Science ®Google Scholar